UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

	OMB APPRO	VAL				
	OMB Number:	3235-0287				
Estimated average burden						
	hours por rosponso	0.6				

longer subject to Section 16. Form 4 or Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
Name and Address of Reporting Person * Treco James					2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP, 26 MAIN STREET, SUITE 101					3. Date of Earliest Transaction (Month/Day/Year) 05/10/2021							Officer (give ti	le below)	Other (s	pecify below)	
(Street)					4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ Fo	6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
CHATHAM, NJ 07928 (City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			Excany (M	2A. Deemed Execution Date, if any (Month/Day/Year) 2A. Deemed Execution Date, if Code (Instr. 8) 3. Transaction (A) or Disposed of (D) (Instr. 3, 4 and 5) Code V Amount (D) Price			(D) Owne Transa (Instr.	Transaction(s) Form: Benefici			f Indirect Seneficial Ownership					
Reminder:	Report on a s	separate line for each		II - Der	·ivati	ive Securit	ies A	Person this fo curren	orm a	who respond are not require valid OMB co	red to resp ntrol numb	ond unles er.			SEC 14	174 (9-02)
1 77:1 0		la m	la. p		., pu			1		ertible securiti	T .		lo n :	0.27 1 0	1.0	1
1. Title of Derivative Security (Instr. 3)	Conversion	(Month/Day/Year)	Day/Year) Execution Date, if any (Month/Day/Year) (Code	Transaction Derivation Code Securities			6. Date Exerc Expiration D (Month/Day/	ate		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (D) or Indirect (I)	(Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option	\$ 1.03	05/10/2021		A		270,882		05/10/2022	2 ⁽¹⁾	05/10/2031	Common Stock	270,882	\$ 0	270,882	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Treco James C/O TONIX PHARMACEUTICALS HOLDING CORP 26 MAIN STREET, SUITE 101 CHATHAM, NJ 07928	X						

Signatures

/s/ Jessica Morris, Attorney-in-Fact	05/12/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C.
- (1) The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.